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PREFACE 
 
 
Smoking is a huge problem in Indonesia and throughout the world. 
Smoking negatively impacts every system in the human body causes many 
types of cancer. Even when smokers want to quit, only 4-7% are successful. 
Researchers are developing approaches to improve success rates, including 
using genetics to guide treatment. Sponsored by the USA National 
Institutes of Health (NIH), Dr. Baurley and colleagues developed the most 
advanced screening technology available for understanding the genetics of 
addiction. This technology is being used by scientists to discover the 
optimal smoking cessation program for smoker’s genetics. 
To use the Smokescreen technology, a DNA sample is extracted in 
a lab from a sample of saliva or blood. DNA samples are placed on the 
Smokescreen Genotyping Array (GTA), which is read by a high throughput 
machine, examining over 500,000 genetic markers in parallel. The raw data 
is then processed in a workflow to call the genotypes for each individual. 
The data is thoroughly quality controlled and available for analysis and 
interpretation by a scientist. 
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Synopsis 
 
 
Genetics influence nicotine metabolism, smoking behavior, 
smoking-related diseases, and response to treatment differently by 
population. As such, Indonesian smokers will have unique characteristics 
that influence these phenotypes. Bina Nusantara (BINUS) University 
invested in two critical areas of research to help Indonesian smokers and 
victims of tobacco-related diseases. 
The first aim was to assess the awareness of physicians and smokers 
to smoking cessation treatment approaches and the possible benefits of 
genetic testing. 
The second aim was to perform a highly innovative research study in 
Indonesia with the Smokescreen technology. The study would be the first 
of its kind in Indonesia and provide the initial data for scientists to develop 
biosignatures of smoking cessation and cancer in Indonesia. 
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Chapter 1 
Study Collaborators 
 
 
Bina Nusantara University contributed one plate of Smokescreen 
arrays (96 DNA samples), supported the BDSRC team, and provided high 
performance computing resources. Dr. Bens Pardamean and Dr. James 
Baurley were co-investigators at this site and focused on project 
management, data management and analysis aspects of the study. 
Hasanuddin University contributed one plate of Smokescreen arrays 
(96 DNA samples), and supported participant recruitment, data, and DNA 
sample collection and storage. Co-investigators included dr. Upik Miskad, 
Prof. Dr. Irawan Yusuf, dr. Ronald Lusikooy, and Prof. Dr. Andi 
Fachruddin. 
BioRealm contributed the Smokescreen toolkit and provided 
biostatistics and statistical genetics support. The BioRealm team consisted 
of Dr. James Baurley, Dr. Carolyn Ervin, Dr. Andrew Bergen, Chris 
Edlund, Stephen McGee, and Carissa Pardamean. 
NVIDIA provided GPGPUs and training to the BDSRC for the 
analysis of the genomic data. Dr. Ettikan Karuppiah was a key person in 
providing these resources to the study. 
RUCDR Infinite Biologics handled the sample processing and 
genotyping for the DNA samples sent to the USA. Dr. Andy Brooks, Dr. 
Jay Tischfield, and Dana Witt-Garbolino provided support to ensure high 
quality data production. 
The University of Southern California (Dr. Jane Figueiredo) was our 
academic partner on the topics of epidemiology and global health. 
Clemson University (Dr. Chris Mcmahan) is our academic partner in 
the biomathematical aspects and potential novel statistical methodologies 
for analysis of the data. 
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Chapter 2 
Smokescreen Genotyping Array (GTA) 
 
 
Smokescreen GTA is a unified platform for genetic research on 
smoking behavior, addiction, pharmacological treatment, and related 
disease. Smokescreen GTA includes 646,247 markers in 23 categories. The 
array design covers genomewide common variation (66%, 82%, and 91% 
in African (YRI), East Asian (ASN), and European (EUR) respectively); 
most of the variation with a minor allele frequency ≥ 0.01 in 1,014 
addiction genes (85%, 90%, and 90% for YRI, ASN, and EUR 
respectively); and, all variation in the known regions related to smoking 
behavior (CHRNA5-CHRNA3-CHRNB4) and nicotine metabolism 
(CYP2A6- CYP2B6). Under  contract HHSN271201300004C (PI:Baurley) 
and  DA033813 (PI:Bergen) funding, 346 study samples, 187 HapMap 
(http://hapmap.ncbi.nlm.nih.gov/), and 1000 Genomes Project (1KGP, 
http://www.1000genomes.org/) samples were selected for Smokescreen 
GTA genotyping. 
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Chapter 3 
Market Research: Physicians 
 
3.1    Introduction 
 
The act of smoking is deeply ingrained in the Indonesian people’s 
daily lives and social culture. Indonesia is the fourth highest cigarette 
consumer in the world after China, Russia, and USA1. As of 2011, 
approximately 60 million people in Indonesia smoke cigarettes on a daily 
basis with an average daily cigarette consumption of 12-13 sticks[2]. 
Indonesia is one of the few countries in the world with much higher rates 
of smoking in males (57%) than females (under 4%)[1]. Smoking initiation 
typically begins around the ages of 17-18 with almost 13% of smokers 
beginning before the age of 15[2]. 
Smoking cessation remains to be the most effective way to reduce the 
impacts of tobacco consumption. The effects of smoking cessation 
materialize much more rapidly than the damaging effects of smoking. 
Additionally, individuals who began smoking at an early age yet stopped 
smoking before the age of 40 has a 90% higher likelihood of avoiding 
tobacco-attributed diseases[3]. A recent survey of Indonesian smokers 
discovered relatively low interest in quitting (only 48% compared to 70% 
for countries such as United States and United Kingdom)[4, 5]. The small 
percentage of Indonesian smokers who did quit, achieved it through no aid 
whatsoever, which further contributes to the difficulty of smoking 
cessation in the nation2. 
A vital basis for low success rates in quitting smoking without aid is 
nicotine’s stronghold on brain physiology. Pharmacotherapy is the most 
effective method to deal with withdrawal symptoms caused by 
neurochemical responses to nicotine absence, thereby increasing the 
chance for long-term cessation by 50-70%. This is particularly true for 
smokers who consume between 10-15 cigarettes per day[6]. A well-
established biological basis to nicotine dependence is found in genetics, 
particularly in variations of the hepatic cytochrome P450 2A6 (CYP2A6) 
and nicotinic receptors (CHRNA) genes. The CHRNA gene family is 
involved in smoking-behavior patterns (e.g. smoking heaviness, time to 
first cigarette per day) through its relation to the neurological reward 
system from nicotine intake[7]. Nicotine metabolism and clearance by the 
liver is heavily influenced by CYP2A6 gene variation; these variants could 
also be useful in determining an individual’s likelihood in lung cancer 
development due to smoking[8]. Moreover, genes relevant to nicotine 
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dependence and metabolism have been found to be essential in determining 
the efficacy of different pharmacotherapy methods as well as in predicting 
risk of smoking relapse[9]. 
Genetic screening and notification have the potential to advance 
patient treatment[10]. Since genetic variation impacts nicotine metabolism, 
smoking behavior, and a cessation method’s efficacy, it becomes a 
significant puzzle in research and for physicians to recommend the best 
approach for a patient wanting to quit. Within the context of smoking 
cessation, genetic screening information has been shown to increase 
cessation success rate and improve cessation interest through heightened 
patient health awareness[11]. Several FDA-approved drugs in the United 
States are available for smoking cessation such as varenicline and 
bupropion. However, physicians are cautious about prescribing them due 
to potential adverse, psychiatric side effects. The nicotine metabolite ratio 
(NMR), which is heavily influenced by CYP2A6 gene variants, has shown 
promise as a biomarker to optimize pharmacotherapy assignments by 
improving efficacy and reducing side effects. From a medical practice 
standpoint, this means that physicians could be assigning nicotine 
dependence treatments to their patients based on a blood test to assess their 
NMR profile in the near future11. While these findings are particularly 
encouraging, there are barriers to using the NMR in practice. Physicians 
may still misunderstand available treatment approaches, genetic 
screening’s role and limitation, and proper ways to interpret and deliver 
results to patients[12]. 
Policy-based interventions in tobacco-product use in Indonesia are 
limited, largely non-governmental supported, and are subject to legal 
interferences by tobacco companies[13]. A strong symbol of this is 
Indonesia’s status as the only Southeast Asian nation yet to sign the WHO 
Framework Convention on Tobacco Control Treaty[2], which 
implementation has proven to be an effective way of reducing tobacco 
consumption[3, 13]. Several investigations that are part of the Quit 
Tobacco International Project based in the province of Yogyakarta find that 
75% of the physicians have a lax attitude about asking patients about their 
smoking habits. 20% of the surveyed physicians (particularly male) are 
smokers themselves while 80% of the physicians believe that smoking up 
to 10 cigarettes per day does not harm a person’s health[2, 14]. However, 
these studies tend to be in a single site and have comparatively small 
samples. Given that the health care providers are a part of the nation-wide 
public health problem, it is important to assess their interest in improving 
care for smoking cessation and smoking-related diseases at multiple cities 
and institutions. One tool that is under-utilized in Indonesia is medical 
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genetics, which ties in strongly with pharmacotherapy and its selection to 
improve efficacy through physician advise. 
The appropriate pharmacotherapy cessation aid can significantly 
impact an individual’s success at quitting smoking, thereby placing a vital 
role on physicians. Due to the lack of official reports on genetic screening 
interest for smoking cessation in Indonesia, this study first investigates 
physicians’ interest in using genetic-based screening within the context of 
smoking cessation consultation. The study also looks at the Indonesian 
health care providers’ interest in information on smoking-related diseases 
as well as physicians’ current access to medical genetics for their medical 
practices. 
 
3.2     Materials and Methods 
 
This study was funded by Bina Nusantara University to evaluate 
physician interest in genetic technologies and screening programs. 
Questionnaires were the primary data collection instrument. The physician 
questionnaire consisted of 12 questions, surveying participants on: medical 
specialty, health care facility affiliation, patient population profile, medical 
research interest, opinion on genetic screening technology, and medical 
genetics tools accessibility. 
Purposive sampling led to the participation of physicians from 
several urban cities across Indonesia, including the greater Jakarta 
metropolitan area, Bandung (West Java), Semarang (Central Java), 
Yogyakarta, Malang (East Java), Palembang (South Sumatra), and 
Makassar (South Sulawesi). All 113 health care professionals responded to 
a hard-copy questionnaire in-person and completed the questionnaire at the 
site of their health care facility posts during their own time. The survey 
targeted physicians with interests in respiratory diseases, nicotine 
addiction, and cancer pathology since they were assumed to have higher 
interest in smoking cessation and smoking-related diseases. The responses 
were entered into a MySQL database by trained data entry staff[15]. All 
statistical analyses were performed on [R], particularly Pearson’s chi-
squared test or Fisher’s exact test to quantify associations between opinions 
of genetic screening usefulness and physicians’ profile[16]. Associations 
with usefulness were tested for each profile category (organization type, 
medical specialty, research interest). For organization type and research 
interest, each individual item’s association with usefulness was assessed as 
well. P-values less than 0.05 were interpreted as statistically significant 
associations. 
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3.3     Results 
 
113 surveys were collected and Table 1 summarizes the physician 
survey’s results. Most of the physicians surveyed were affiliated with a 
clinic (56%). 63% of the physicians were general practitioners, reflecting 
the predominant affiliation to clinics. The most dominant research interests 
were respiratory diseases (35%) and nicotine addiction (28%). 
Overall, 81% (n = 89) of total respondents indicated that genetic 
screening information for smoking cessation would be useful. Institutional 
affiliation and usefulness have a statistically significant association (p = 
0.018). Individual categories for research interest were tested only 
independently against usefulness since a physician could select more than 
one research interest. The usefulness rating was significantly associated for 
interest in cancer pathology (p = 0.005) and in other research fields 
(grouping among 13 categories written-in by the physicians; p = 0.003). 
Usefulness was not significantly associated with interest  
 
Table 1. Profile of surveyed physicians - Genetic Screening Usefulness 
for Smoking Cessation 
Category Total N  
(%) 
Very 
Useful 
Somewhat Not p-value 
Institutional  Affiliation     0.018 
Hospital 48  (44) 21  (45) 22  (48) 3 (7) 0.043 
Clinic 62  (56) 16  (26) 30  (49) 15  0.108 
Medical Specialty     0.222 
General Practitioner 71  (63) 19  (28) 38  (55) 12   
Non-GP 42  (37) 18  (44) 17  (41) 6 (15)  
Medical Research      
Respiratory Diseases 40  (35) 17  (47) 12  (33) 7 (19) 0.060 
Cardiovascular Diseases 19  (17) 8   (42) 6   (32) 5 (26) 0.423 
Cancer Pathology 9   (8) 7   (78) 2   (12) 0 (0) 0.005 
Nicotine Addiction 32  (28) 15  (47) 15  (47) 2 (6) 0.074 
Substance 7   (6) 1   (14) 5   (72) 1 (14) 0.423 
Others 34  (30) 5   (15) 20  (59) 9 (26) 0.003 
 
in respiratory disease and nicotine addiction (p = 0.06 and 0.074 
respectively). Medical specialty was not significantly associated with 
usefulness ratings (p = 0.222). 
Table 2 summarizes the physicians’ expected and current experience 
with genetic screening. The survey found that 42% of physicians were 
interested in genetic information on respiratory, cardiac, and psychiatric 
diseases. 23% were interested in genetic information on addiction. 42% of 
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physicians believed that they did not have enough knowledge to decide 
what type of information from genetic screening would be useful. 
Nonetheless, 70% of those who deemed themselves to lack knowledge 
stated that genetic screening information would be useful at some level for 
smoking cessation. 89% of physicians stated that their affiliated institutions 
were limited in medical genetics services and facilities. 
The survey also included a question that asked physicians to report 
the percentage proportion of their patients who are current smokers. 27% 
(N = 30) of the surveyed physicians could not provide a response to this 
question. Based on the physicians who did respond to the question (N = 83; 
73%), it was found that smokers, on average, comprise 45% of a 
physician’s patient list.  
 
Table   2.  Indonesian   physician   and  genetic screening 
Existing Medical Genetics and  Related n % 
Services (n = 113)   
Genotyping 9 8 
Sequencing 3 3 
None - institution limited  in this  area 101 89 
Genetic Screening Information Interest (n = 113)   
Genome-wide analysis 9 8 
Addiction-related gene screening 26 23 
Pharmacogenetics 22 19 
Respiratory,  cardiac,  psychiatric  diseases 48 42 
screening   
I don’t  know - better leave decision  to experts 47 42 
   
3.4     Discussion 
 
A 2011 survey performed by the World Health Organization (WHO) 
on Indonesian smokers finds that only two-thirds of the surveyed patients 
recalled ever having a physician ask them about their smoking status [2, 
14]. Our study complemented this finding with 27% of the surveyed 
physicians not knowing how many smokers they were currently treating. 
The lack of knowledge on patient smoking status is worrisome since 
proactive health care providers play a crucial role in smoking cessation 
success. Physicians are recommended to practice the 5 A’s in smoking 
cessation counseling: Ask, Advise, Assess, Arrange, and (re-)Assess[17]. 
12 
 
It is also important for physicians to understand how to interpret genetic 
screening results and effectively relay the findings to patients[18]. This is 
especially true given major concerns that primary care physicians and 
general practitioners have over the sensitivity and complexity of medical 
genetics information[19]. 
Despite the relatively low interest in patient smoking status and 
limited resources for genetic screening available to Indonesian physicians, 
we found a positive response towards medical genetics for smoking 
cessation. Even 70% of those who did not know what type of information 
they would like from genetic screening stated that having it as a medical 
practice tool would be useful for at least smoking cessation. This is 
promising because 56% of the physicians surveyed were based in clinics. 
Compulsory community clinics remain the most affordable and most 
widely-visited form of health care for the Indonesian population, making 
these clinics the most far-reaching source of information on smoking 
cessation and smoking-related diseases[20]. 
One setback in the survey collection was the oversight of not 
interviewing the physicians in-person. The logic to this was to respect the 
privacy of the physicians by having them complete the questionnaires at 
their own time. However, this led to some missing values to the 
questionnaires. The survey also did not have a direct question to gauge how 
comfortable physicians would be in implementing or incorporating genetic 
screening information into their daily medical practices if the tools became 
available to them, taking upon the role of a provider and interpreter of 
medical genetics information. 
Physician opinion is one side of the story when it comes to smoking 
cessation efforts on a public health scale. Opinions and attitudes of patients 
are also crucial pieces of the puzzle. Therefore, the next step to our research 
is to survey smokers’ opinion on genetic screening for smoking cessation. 
We observed an optimistic and promising interest in genetic 
screening among Indonesian physicians for smoking cessation and related 
diseases despite limitations in the availability of medical genetics facilities. 
Most physicians who stated that they lack the proper knowledge to specify 
information they wish to gain from genetic screening still believe that the 
tool would be useful for smoking cessation consultation and nicotine 
dependence treatment. Therefore, education on information use and 
interpretation, facility and technology availability, and most likely 
monetary costs would be barriers in efforts to implement genetic screening 
for smoking cessation consultation in Indonesia.  
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Chapter 4 
Market Research: Smokers 
 
 
4.1     Introduction 
 
Smoking is a leading cause of preventable death in Indonesia and 
around the world. Yet, 1 in 3 males in Indonesia smoke because of the 
highly addictive properties of nicotine and complex behavioral and social 
factors. Genetic factors play a very significant role in how a smoker 
metabolizes nicotine, how dependent they are, and how they respond to 
treatment. Given the number of treatments available, both 
pharmacotherapies and behavioral, the best smoking cessation path varies 
from individual to individual. Optimizing the path for smokers wanting to 
quit will reduce smoking rates and reduce the expenses related to healthcare 
and lost productivity due to smoking. Research on which genetic factors 
are important to smoking cessation success and how best to translate these 
findings into real-world applications is ongoing. 
Recognizing the need for improving the understanding of the 
genomics of addiction and developing screening for personalized smoking 
cessation approaches, we developed a state-of-the-art genetic screening 
platform called Smokescreen (Baurley, et al., 2016). The technology 
captures genetic markers of nicotine dependence and treatment approaches, 
and to addiction in general. The technology includes hardware for 
capturing raw data and software for analyzing and interpreting the data. 
The platform works by a DNA sample (extracted from saliva or blood of 
smokers) being sent to a lab set up to use the technology. The sample is 
processed on a custom assay. The genomic data is then cleaning and 
analyzing and then results are returned. The Smokescreen process is being 
heavily used in nicotine and tobacco research in the United States and is 
beginning to be used in research within Indonesia. 
The evidence is accumulating for a panel of genetic markers, whose 
results could be used to guide smoking cessation therapies for smokers 
wanting to quit. The value of screening for optimized smoking cessation 
treatment is well known in the US. It is estimated that even an improvement 
in smoking cessation success rates of 1% would represent an annual 
savings of US$ 3 billion in expenses related to health-care and lost 
productivity. There is a large push for translation of research to smoking 
cessation application in the U.S. The market barriers in the U.S. include 
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government regulation for diagnostic testing as well as acceptance of new 
pharmacotherapies and genetic screening by smokers and physicians. The 
smoker must want to quit and embrace the provided plan and the physician 
must accept the technology and support its guidance. 
There is interest in the marketability of genetic screening 
technologies in Indonesia, a country highly impacted by smoking and 
attributable disease. For an initial assessment of the market, we surveyed 
the end-user of new technologies for smoking cessation – current smokers 
in Jakarta, Indonesia. With this initial assessment, we can naturally extend 
it to physicians that assist smokers in quitting, and more largely the 
pharmaceutical companies and health-care networks that would 
significantly benefit from improved smoking cessation treatment and 
reduced smoking rates in Indonesia. 
In this report, we present results from a market survey designed to 
characterize smokers, assess availability of cessation treatments and 
screening methods, and identify barriers and opportunities for genetic 
screening technologies. Motivated by the health impact of smoking, the 
questions were designed to help characterize smokers in Indonesia, 
particularly in their experiences towards smoking cessation attempts and 
methods, as well as in their opinions towards factors influencing smoking 
cessation and medical genetics. This will provide an initial market 
assessment for genetic screening for optimal smoking cessation treatment 
in Jakarta. Additionally, this work will help capture the requirements for 
developing and customizing products and services related to Smokescreen 
technology used in the U.S. for Indonesian populations. 
The tobacco industry has a significant and active role in Indonesia 
due to the country’s lax regulations on tobacco product advertisement and 
its low tobacco taxation [17, 15]. Aside from non-stringent government 
regulations and the aggressive marketing by tobacco companies, the act of 
smoking is deeply ingrained in the Indonesian people’s daily lives and 
social culture. Indonesia is the fourth highest cigarette consumer in the 
world, after China, Russia, and the US [34]. The lack of excise tax 
regulations on tobacco products leads to low cigarette prices in Indonesia. 
This creates a ripple effect of decreased quality of life, especially amongst 
low income communities. A regular pack of twenty cigarettes cost under 
USD $2 in Indonesia, with some brands closer to $1 per pack [34]. It is 
estimated that an average low-income household spends 15 times more on 
tobacco than on healthcare and 9 times more on tobacco than on education. 
Tobacco purchase (12% of total monthly spending) takes precedence over 
utility bills (water, electricity, phone bills), housing rent, and protein food 
sources; cigarette spending trails behind only the purchase of rice (22% of 
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total monthly spending) [17]. According to a joint WHO and World Bank 
study in 2011, 5% of GDP per capita is spent on buying an average of 100 
packs of cigarettes. 
As of 2011, approximately 60 million people in Indonesia smoke 
cigarettes on a daily basis with an average cigarette consumption of 12-13 
sticks per day [17, 15]. Smoking initiation typically begins around the ages 
of 17-18 with almost 13% of smokers beginning before the age of 15 [17]. 
Gender-wise, more male Indonesians smoke (57%) than females (4%). 
However, all population sub-groups, particularly children, are affected by 
the serious and negative impact of second hand smoking (SHS) exposure. 
Close to 134 million non-smokers in Indonesia are exposed to SHS 
regularly, which is not surprising given that over 70% of Indonesians live 
in a household with at least one smoker [3, 17]. 
Additionally, the lack of smoking bans in public places exposes many 
individuals to SHS at their place of work and most social and public places. 
Tobacco-attributed death is estimated to be over 200,000 annually in 
Indonesia. One in five male deaths and one in ten female deaths are traced 
back to regular smoking consumption and/or exposure [34]. The main 
causes of tobacco mortality in Indonesia are cardiovascular diseases, 
malignant cancers (particularly lung), and chronic, obstructive respiratory 
illnesses [3]. Approximately, 11 trillion Indonesian rupiah (1.2 billion 
USD) per year is spent on medical care related to tobacco-attributed 
diseases [3]. Non-smoking women exposed to SHS at home have an 
estimated 25% increased risk for lung cancer and an estimated 23% to 25% 
increased risk for cardiovascular diseases [3]. 
With nicotine addiction being tied closely to brain chemistry, 
pharmacotherapy is the most effective method to alleviate withdrawal 
symptoms, especially for moderate smokers [29]. Several 
pharmacotherapies for smoking cessation, such as nicotine replacement 
therapies, varenicline, and bupropion, have been shown to be effective 
treatments, especially when used in combination [19, 16]. Their availability 
vary considerably throughout the world [27]. Behavioral therapies are 
common aids for smoking cessation as well, such as medical counseling 
(in-person or remote counseling) and support group meetings [13]. Using 
behavioral therapy in combination with a form of pharmacotherapy 
protocol has a small but significant impact, increasing success rate by 10-
25% compared to pharmacotherapy approaches alone [30]. 
Given the complexity of nicotine addiction [4], the wide array of 
treatment approaches [16], and the cost of development of new therapies 
[22], improvements of currently available treatments is a priority [29, 8]. 
With medical genetics being applied to smoking cessation, selecting the 
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most effective treatment protocol for individual smokers is becoming 
possible [7]. For example, assigning treatment by an individual’s nicotine 
metabolism, has been shown to improve effectiveness of varenicline and 
nicotine patch [18]. In addition, genetic variants in the CHRNA5 nicotinic 
receptor has been shown to influence the efficacy of various nicotine 
replacement therapies [10]. The refinements of treatment protocols based 
on medical genetics information may improve the likelihood of cessation 
and minimize side effects [26]. With rapid advancements in technology and 
decreasing cost in DNA sample collection and processing, many facets of 
smoking cessation therapy can be improved through genetic-based 
screening [6]. 
 
4.2     Methodology 
 
This market survey was funded by Bina Nusantara University to 
gather opinions on smoking cessation ability, as well as beliefs on factors 
that influence cessation success. The 31-question survey was developed to 
capture information on smokers in three areas: demographics, smoking 
behavior, and smoking cessation. Current smokers were recruited in 2015 
from the greater Jakarta metropolitan area due to its proximity to the Bina 
Nusantara University campus. Occupations were categorized based on 
Indonesia’s official government identification card; the categories are: civil 
servant, entrepreneur, educator, and, student. None of the occupations were 
targeted specifically. There were 111 participants. Preliminary question 
asking smokers on their willingness to participate in the survey were 
administered. Upon agreement, a hard-copy of the questionnaire was used 
as a data collection instrument. The questionnaire was self-administered 
and completed primarily at the workplace and campuses (for students) with 
a few completed at public places such as restaurants and food courts. To 
reduce incompleteness in survey responses, trained interviewers verified 
missing responses with participants. The data were entered from hard-copy 
questionnaires into a database that was maintained with mySQL [33]. The 
descriptive statistics were generated with [R] [23]. 
 
4.3     Results 
 
The demographics of the 111 participant smokers are summarized in 
Table 3. The age range of participants was between 18 and 60 years old 
(mean of 32 years old). Over 90% of the participants were males. 
Additionally, most were office workers and students (70%), head of 
households (47%), and have at least a high school education (95%). 
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Table 4 summarizes the smoking habits of the participants. 47% 
smoked between 10 and 20 cigarettes per day while 19% were heavy 
smokers (over 20 cigarettes per day). We found that 75% of the surveyed 
participants have attempted to quit smoking at least once. However, less 
than 20% of those who had attempted were successful in maintaining their  
 
Table   3.  P a r t i c i p a n t  D e m o gr a p h i c s  
Average Age (SD) in years  
 
32.4 (11.7) 
Gender  
 
Count  (%) 
Male  
 
92  (83) 
Marital Status   
Married  
 
53  (51) 
Occupation   
Entrepreneur  
 
5  (5) 
Office Worker   42 (38) 
 Civil Servant 
 
8  (7) 
Student   36 (32) 
 Educator  
 
18 (16) 
Other  2 
 
(2) 
Role in Household   
Head of Household  52  (47) 
Wife 5  
 
(5) 
Child/Dependent  
 
54  (49) 
Highest Level of  Education   
Elementary School or Less  
 
3 (3) 
Middle  School   3 (3) 
 High school  
 
49  (44) 
Bachelor’s  and  beyond  56 (51) 
 Household Size   
2  13  (12) 
3  19  
 
(17) 
4  40  
 
(37) 
5  26    (24) 
 6  
 
6  (6) 
> 6  4  (4) 
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cessation for over six months; even then, these participants had relapsed 
and had continued smoking since all participants in the survey were current 
smokers. 26% of the survey participants reported to have had an illness 
due to smoking and 19% reported to have seeked medical care related 
to smoking. 
Table 5 further divides the participants based on whether they had 
attempted smoking cessation or not. For those who had attempted 
cessation, social environment (36%) and withdrawal symptoms (41%) 
were the most frequently selected responses for why they believed that 
their attempts failed. Most quit attempts were unaided (74%) and no 
participant used pharmacotherapy to attempt quitting. While only 3 
(4%) smokers attended a smoking cessation clinic, 11 (14%) received 
consultation from a doctor, indicating the need of increasing the 
involvement of primary care providers in smoking cessation. Nearly 
four-fifths of those who never attempted cessation stated that they 
wished to quit smoking in the future. 39% felt they could quit with no 
aid, while 44% admitted that their addiction is the primary reason they 
have not attempted to quit. Few smokers were aware of screening using 
medical genetics for cessation in both groups. 
Table 6 lists responses on perception on how certain factors affect 
cessation ability as well as responses to positive and negative reactions to 
outcomes related to medical genetics and smoking cessation ability. Social 
environment, exercise, stress level, and satisfaction gained from smoking 
were the most frequently selected factors in terms of importance on 
cessation difficulty.  Most participants disagreed that they would feel 
hopeless if they were to find out via medical genetics that cessation would 
be difficult. Many also responded that they would want to find out more 
about their children’s and family risk of addiction and ability to quit 
smoking. Overall, 83% of the smokers felt that genetic screening would be 
useful if it could indicate cessation difficulty and would lead to their 
consulting their doctors for advice. The majority of responders were 
interested in knowing the conditions that could be assessed through medical 
genetics in relation to smoking cessation and smoking-related risks. 
However, reports on higher likelihood of suffering from cardiac arrest, a 
known smoking risk factor, would have no effect in motivating lifestyle 
changes in over three-quarters of the respondents. 
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Table 4.  Smoking-Related Characteristics 
Smoking Initiated (Years Ago) Counts (%) 
< 5  24 (22) 
5 - 10  
 
28 (26) 
11 - 20  
 
31 (28) 
21 - 30  
 
14 (13) 
> 30  12 (11) 
 Cigarettes per Day  
< 10  36 (33) 
 10 - 19  51 (47) 
 20 - 29  18 (17) 
 ≥ 30 
 
3 (3) 
 Monthly Cigarette Expense   
< Rp.  100,000  23 (22) 
 Rp.  100,000 - 300,000  
 
38 (36) 
Rp.  300,000 - 500,000 30 (28) 
> Rp.  500,000  16 (15) 
 Illness Due to Smoking  
Has occurred  29 (26) 
 Have not occurred  
 
82 (74) 
Medical care seeked related to smoking  
Yes  21 (19) 
 No  90 (81) 
 Cessation Attempted  
Yes  
 
82 (75) 
No  28 (25) 
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Table 5.  Questions on Smoking Cessation Attempts 
Have attempted to quit (N = 82) Have not attempted to quit (N = 28) 
 
Reason for Quit Attempt Count (%) 
Reason for No Quit 
Attempt 
Count 
(%) 
Social or family urging  
to stop 
18 (22) Feel in control/no need 15 (56) 
Health reasons/want  
to be  healthier  
52 (63) 
Addiction/need to 
smoke 12 (44) 
Financial Reasons 12 (15) Quit in the Future  
First Quit Attempt (Years)  Yes 
 
22 (79) 
< 5  
 
60 (74) No  
 
 6 (21) 
6-10  8  (10) Method if quitting in the future   
> 10  13 (16) 
 
Rehabilitation 0 (0) 
Quitting Method  Smoking Cessation Clinic  4 (14) 
Rehabilitation  
 
4  (5) Pharmacotherapy  
 
2 (7) 
Smoking Cessation Clinic
  
3  (4) Doctor Consultation  
 
 7 (25) 
Pharmacotherapy  
 
0  (0) Hypnotherapy      4 (14) 
 Doctor Consultation  
 
11 (14) No aid  
 
11 (39) 
Hypnotherapy  3 (4) Involve Medical 
Treatment  
No aid 59 (74) Yes 10 (36) 
Attempt Outcome  No 18 (64) 
 
Successful  13 (16) 
Aware of medical 
genetics for cessation  
 
 
Not Successful  
 
69 (84) Yes      5 (18) 
Reason for Non-Success  No  23 (82) 
 Social pressure  22 (36)   
Cannot overcome  
withdrawal symptom 25 (41) 
 
 
Relapse for other reason 
 
14 (23)   
Aware of medical  
genetics for cessation 
   
Yes  9 (11) 
 
  
No  73 (89)   
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4.4     Discussion 
 
This market survey has characterized current smokers within an 
urban city in Indonesia, namely Jakarta. The questions of the survey 
encompassed participants’ cessation attempts and opinions on factors 
influencing cessation abilities. As is often the caveat with surveys, there 
were some notable limitations. The sample was generally small due to the 
labor-intensive process to recruit and minimize missing information from 
each participant. The survey was also conducted in only in Jakarta due to 
the location of Bina Nusantara University and convenience. Therefore, 
generalizability of findings to other areas of Indonesia is limited. In 
general, participants tended to give more general responses until asked to 
be more specific. For instance, when responding to how many years ago 
smoking was initiated, many participants responded with a range rather 
than a specific number of years. 
Despite the seemingly common knowledge of risks associated with 
smoking, it is still prevalent worldwide and in Indonesia. Smokers tend to 
underestimate their susceptibility to diseases caused by smoking and are 
unaware of many facets of how smoking is dangerous [32, 28, 14]. Among 
the major risk factors of smoking is sudden cardiac arrest [35]. However, 
we found that few respondents reported that this would motivate them to 
quit or change their smoking habit if they were informed by medical 
genetics to be more susceptible towards a cardiac arrest event. Instead 
between 78-80% responded that it would have no effect on their behavior. 
Surveying a target population before marketing medical screening or 
treatments is important to avoid misinformation and skepticism [31, 5]. 
Therefore, evaluating the opinions and attitudes of Indonesian smokers 
towards smoking cessation and genetic screening is essential for 
commercialization. We showed that assumptions on common knowledge 
about the dangers of smoking or ways to quit smoking should not be made. 
In this market survey, it was found that a majority (little over two-thirds) 
of the participants plan on quitting in the future, mainly without any form 
of assistance. For those who have attempted cessation, none stated that they 
used pharmacotherapies. With these responses, it was sensible that very 
few were also aware of the utility of genetic screening for smoking 
cessation. 
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Table 6. Opinions and Attitudes towards Factors that Potentially 
Influence Smoking Addiction 
Factors on Smoking Cessation 
Ability 
Not 
Important 
(%) 
Important 
(%) 
 
Diet 64  (59)   45  (41)  
Exercise 33  (30)   76  (70)  
Social 16  (15) 92  (85)  
Culture 45  (42) 63  (58)  
Alcohol 60  (55) 49  (45) 
 
 
Drugs 62  (57) 47  (43) 
 
 
Insurance 65  (60) 43  (40)  
Luck 78  (73) 29  (27)  
Stress 21  (19) 88  (81)  
Ethnicity 91  (84) 18  (16)  
Satisfaction from smoking 19  (18) 89  (82)  
Response to Medical Genetics 
Information on Cessation Difficulty Agree (%) Disagree (%) 
 
No hope of ever quitting 14  (13) 92  (87) 
 
 
Determine if offspring has same risk 79  (74) 28  (26)  
Advice other family not to smoke 99  (92) 9  (8)  
Feel that a genetics test was useful 90  (83) 18  (17)  
Consult a doctor for quitting method 90  (83) 18  (17)  
Conditions  of   Interest  for Genetic 
Report  Yes (%) No (%) 
 
Relative high risk for lung cancer, 
diabetes, cardiac arrest 60  (57) 46  (43) 
 
The best method for smoking 
cessation 70  (64) 39  (36) 
 
Have lower risk for lung cancer 
despite smoking 64  (59) 44  (41) 
 
Effect  of   Knowing Higher Cardiac 
Arrest Likelihood 
 More likely 
(%) 
Less likely 
(%) 
Same  
(%) 
Quit smoking 12  (11) 11  (10) 83  (78) 
Reduce smoking level 10  (10) 12  (12) 82  (79) 
Increase exercise frequency 7  (7) 11  (10) 88  (83) 
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The use of pharmacotherapy is an effective way to assist smokers 
during the onset of withdrawal symptoms, especially given that cravings 
were reported as the main reason for a non-successful cessation attempt and 
as the reason for never attempting to quit. Therefore, pharmacotherapy can 
be beneficial for Indonesian smokers, helping them overcome nicotine 
withdrawal symptoms. In addition to genetics, cessation ability is heavily 
influenced by environment, lifestyle, and psychological factors [12]. Based 
on the market survey, Indonesians are more aware of psychosocial and 
lifestyle factors but not the biological factors that influence smoking 
cessation. They believed that social environment, exercise, and stress were 
the most important factors influencing cessation success. As a result, 
medical consultation and support groups could benefit Indonesian smokers 
attempting cessation as well. 
Several questions were included in the questionnaire to evaluate the 
reaction towards good and bad news from a genetic test. Based on the 
survey, Indonesians would reap more benefit than harm from the results of 
genetic screening stating that they would have difficulties with smoking 
cessation. Additionally, the majority of respondents stated that they would 
not feel hopeless upon finding out that they had higher risk for smoking-
related diseases. Gauging how smokers believe they could benefit from 
medical genetics is important [31]. The market survey found that the 
information that interests Indonesian smokers the most is to determine the 
best cessation method for them. There was also interest in determining their 
level of risks for smoking-related diseases. 
Beyond benefits for themselves, most of the participants stated that 
they would like to know if their children had the same predispositions and 
would encourage their families and friends to quit smoking. Previous 
studies have shown that smokers having more concern over whom they 
affect than themselves; particularly when their children are involved [24]. 
Children as a motivation for cessation could be particularly useful since 
many Indonesian smokers are heads of households living in homes with 3-
5 members. 
The market survey discovered that genetic screening would 
encourage smokers to seek medical help. Market introduction should be 
done cautiously to avoid the “magic bullet” perception and any other 
misperception on the capabilities of genetic screening or a particular 
treatment [21, 25]. The greatest market barrier would be raising awareness 
and educating the population on treatments available for them; this in turn 
poses a significant barrier to adding medical genetics to smoking cessation 
therapy. None of the surveyed participants used pharmacotherapy in their 
cessation attempts. This was expected given that nicotine replacement 
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therapies, such as patches and gums, are not available in Indonesia but are 
available in neighboring countries, such as Singapore [11] while 
varenicline is available in Indonesia but at a steep price [9]. 
There is a promising overall attitude towards genetic screening for 
smoking cessation. Psychotherapeutics combined with counseling could be 
one avenue to aid in cessation [1], as could providing in-patient treatments 
for smokers [20]. With advancements, refinements, and a variety of 
combinatorial aids for pharmacotherapy and behavioral treatment protocols 
underway, implementation and feasibility testing suitable to Indonesians in 
various parts of the country could be done in a more structured and 
informed manner in the future. 
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Chapter 5 
Indonesian Smokescreen Genotyping Study 
 
 
5.1     Introduction 
 
Smoking is deeply ingrained in the social culture of a significant 
portion of the Indonesian population, comprising the fourth highest 
cigarette consumer in the world [1]. According to a 2011 World Health 
Organization estimate, 5% of GDP per capita of Indonesia is spent on 
buying an average of 100 packs of cigarettes and takes precedence over 
many essential expenditures such as healthcare, education, and housing [2]. 
On top of the financial cost, it is common knowledge that long-term and 
second-hand smoking are associated with many complex, terminal diseases 
[3, 4]. Fortunately, the effects of smoking cessation materialize much more 
rapidly than the damaging effects of smoking. Additionally, individuals 
who began smoking at an early age yet stopped smoking before the age of 
40 has a 90% higher likelihood of avoiding tobacco-attributed diseases [5]. 
Therefore, smoking cessation remains to be the most effective way to 
reduce the impacts of tobacco consumption. 
A significant reason behind the low success rates in smoking 
cessation with- out aid is nicotine’s stronghold on brain physiology, which 
in turn is heavily influenced by an individual’s genetic makeup [6, 7]. The 
CYP2A6 gene plays a major role in the nicotine metabolism pathway [8, 
9]. An individual’s nicotine metabolism affects the level of circulating and 
sequestered nicotine and thus nicotine intake [10, 11]. Given the 
complexity of nicotine addiction [12], the wide array of treatment 
approaches [13], and the cost of development of new therapies [14], 
improvements of currently available treatments is a priority [15, 16]. With 
medical genetics being applied to smoking cessation, selecting the most 
effective treatment protocol for individual smokers is becoming possible 
[17]. For example, assigning treatment by an individual’s nicotine 
metabolism, has been shown to improve effectiveness of varenicline and 
nicotine patch [18]. In addition, genetic variants in the CHRNA5 nicotinic 
receptor has been shown to influence the efficacy of various nicotine 
replacement therapies [19]. The refinements of treatment protocols based 
on medical genetics information may improve the likelihood of cessation 
and minimize side effects [20]. With rapid advancements in technology and 
decreasing cost in DNA sample collection and processing, many facets of 
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smoking cessation therapy can be improved through genetic-based 
screening [21]. Given the complex biological basis of nicotine addiction, 
the next logical step would be to begin an initiative dedicated towards 
resolving issues tied to smoking cessation among the Indonesian 
population. However, a strategy of this kind has not been introduced in 
Indonesia. 
The United States is attempting to solve these complex, biomedical 
questions through the Precision Medicine Initiative (PMI) [22]. Early in 
2015, President Obama and the National Institutes of Health announced the 
Precision Medicine Initiative that aims to build a research cohort of one 
million to use the diversity present within a population as the foundation in 
designing disease treatment and prevention [23, 24, 25]. Smoking cessation 
and diseases attributable to smoking were listed among public health issues 
to be addressed through the PMI approach of curating uniform data from a 
diverse population [26]. 
A methodology and tool we have developed, the Smokescreen 
Genotyping Array is a comprehensive DNA variant assessment tool, with 
focused content for addiction and pharmacogenetic analysis [27]. We have 
prototyped the Smokescreen technologies in pilot studies of smokers in the 
United States [28]. Following our current work in the United States and the 
nation’s PMI initiative, we have applied the same methods to studies of 
Indonesian smokers. We have designed and piloted a survey for Indonesian 
smokers and physicians in order to determine the opinions of both groups 
on medical genetics and smoking cessation treatment. With these existing 
components and experiences, we are ready to design, build, and implement 
the Indonesian Biobank that holds clinical and genetic data from 
Indonesians within the context of nicotine addiction, smoking cessation, 
and preventable disease (e.g., cancer). This project has established the first 
biobank in Indonesia focused on major health issues. This project has laid 
the groundwork for sustainable capabilities in genotyping and 
computational technologies, databases and sample processing for the 
Indonesian Biobank, and collaborations with researchers worldwide. 
 
5.2     Study Objectives 
 
The goal of this study was to build upon our current research efforts 
in nicotine addiction, smoking cessation, and attributable diseases in 
Indonesia. We aimed to establish the Indonesian Biobank that would be 
used to study nicotine addiction and cancer based upon a robust and diverse 
population cohort as well as a detailed and uniform data bank. In the short 
term, the project begins to determine factors that are crucial in developing 
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tools and treatment protocols tailored towards Indonesian smokers. In the 
future, this project will act as a template for precision medicine initiatives 
focused at understanding and treating other complex health issues facing 
Indonesians. Specifically, we implemented prototypes of the following: 
 
 Collect DNA samples, phenotypes, and exposure variables on 
Indonesians based on a cohort selected from epidemiological 
studies of colorectal cancer that are currently underway at 
Hasanuddin University. 
 
 Develop capabilities to process DNA and organize clinical and 
genetic data from multiple studies on nicotine addiction, smoking 
cessation, and attributable diseases for statistical analyses. 
 
 Perform genome-wide genotyping using the Smokescreen 
Genotyping Array on collected DNA samples. 
 
 Perform association analyses of known factors that influence 
nicotine addiction, smoking cessation, and attributable disease (i.e. 
colorectal cancer). 
 
 Identify domestic and international partners to build and sustain a 
consortium for genomic research in Indonesia; thereby, allowing for 
the project to continue to provide value. 
 
5.3    Methodology 
 
Hasanuddin University (UNHAS) has ongoing epidemiology studies 
involving smokers and cancer. Though a collaboration with UNHAS, we 
have collected data and samples for colorectal cancer cases and controls. 
More than 192 cases and controls were selected to be extensively 
characterized. This sample size was selected based on the number of 
available unique spaces on the Smokescreen Genotyping Array plates; and 
sufficient to replicate known associations with moderate-to-large effects. 
A de-identified identifier was assigned to each individual and used to link 
phenotype, exposures, DNA samples, and genotyping results. The ethics 
committee at Hasanuddin University reviewed and approved study 
protocols. 
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5.3.1 Phenotypes and Exposures 
Previous questionnaires, experts in the field, and the PhenX toolkit 
was used for standardized measures on phenotypes and exposures [32, 33]. 
PhenX has suggested collection forms, protocols, and data dictionaries for 
substance abuse and addiction, including tobacco use and quit attempts. As 
needed, forms were translated to the Indonesian language by clinical and 
research staff from both Hasanuddin University and Bina Nusantara 
University to ensure proper and accurate translations. Measures were 
nominated by our scientific advisors to increase the number of comparable 
measures with related studies using the PhenX toolkit [34]. For cancer 
patients, the questionnaire was expanded with questions from the Cancer 
Patient Tobacco Use Questionnaire Core and Extension [35]. 
 
5.3.2 DNA Samples 
DNA samples from blood were collected from cases and controls, 
both groups included smokers. These samples were stored at UNHAS. In 
the future, DNA Genotek Oragene (Ottawa, Canada) brand collection may 
be used to collect salivary samples for DNA extraction [36, 37, 39]. For 
blood samples, standard protocols for collection and storage were used by 
UNHAS researchers. 
 
5.3.3 Build Capacity for Genomics Research 
Developing tobacco research capacity in Indonesia requires an 
international team with expertise in clinical research, epidemiology, 
biostatistics, genetics, and computer science. We have developed prototype 
IT tools for collection and analysis of genomic research data - both clinical 
and genetic - in Indonesia. 
 
5.3.4 Physical Infrastructure 
Uniform collection and extraction of DNA from blood samples were 
performed by UNHAS and MRIN clinical staff. The Indonesian Biobank 
was located in a physically secure area at UNHAS with back-up power and 
temperature controls. Samples were tracked using their Laboratory 
Information Management System (LIMS). 
 
5.3.5 Database and Web-based Application 
A secure relational database was developed by Bina Nusantara 
University to store individual-level clinical and genomic data. This 
database was implemented in PostgreSQL. A web-based application was 
developed to facilitate secure, multisite entry of data. The application has 
built-in checks to ensure the quality of data entry into the system. A user 
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interface was created for this application, enabling user interactions with 
the system to generate queries and to produce necessary reports and 
analysis datasets. 
 
5.3.6 Tables, Figures, and Listings (TFLs) 
Template TFLs were created to report and summarize the data for 
measures, DNA samples, and genotyping results. A specification document 
was created and will serve as a template for additional collections. The 
document, when finalized, briefly summarize general programming 
instructions for variables definitions, subgroup definitions, and genotyping 
classifications. The document contains template outputs categorized by: 
demographic and study characteristics, DNA, genotyping and quality 
control, and analysis for smoking and cancer outcomes. Each templates 
includes the analysis population used, definitions for column variables and 
totals, analysis variables used, statistics and calculation methods, numeric 
precision and formatting, and patient subsetting. TFL outputs and reporting 
were implemented in [R] and can be run on demand. 
 
5.3.7 Sample Genotyping and Quality Control 
Extracted DNA from study samples were genotyped on the 
Smokescreen Genotyping Array [27]. This array is a custom, genome-wide 
array for research on smoking behavior, addiction, pharmacological 
treatment, and related disease. It contains 646,247 SNPs and indels for 
discovery and characterization studies. 1,014 genes relevant to addiction 
and smoking-related phenotypes were identified by literature search, expert 
nomination, and biological knowledge-bases. The array contains nearly 
complete coverage of the chr19q13.2 nicotine-metabolizing enzyme genes, 
CYP2A6 (612 markers) and CYP2B6 (1,628 markers). 
Genotypes and sample-level quality statistics were generated from 
raw CEL files using the Affymetrix Power Tools software suite and 
Smokescreen library and annotation files (r2). In brief, samples with a Dish 
QC value under 0.82, stage I genotyping call rate under 97%, scan failures, 
positive controls added by the genotyping lab, samples with discordant 
genotyped vs. reported sex, monozygotic twins, siblings, and replicate 
samples with the lowest call rate were removed. The Affymetrix 
SNPolisher software was used to determine the best probeset for each 
marker and categorize markers based on quality. 
A quality controlled dataset was created and linked to the Indonesian 
Biobank PostgreSQL database developed. Unused DNA may be stored in 
the Indonesian Biobank for future use. 
 
36 
 
 
5.3.8 Genomic Association Analysis 
The tables, figures, and listings designed and programmed were 
performed for each measure. Chi-square tests (for categorical variables) 
and F-tests (for continuous variables) were used to test for differences in 
groups. A significance level of 0.05 will be used for these tests. 
Generalized linear models were used to evaluate the relationships 
between smoking and cancer outcomes and genetic and clinical variables. 
The evaluation includes adjustments for potential confounders, such as age, 
ancestry, gender, and body mass index. Ancestry was estimated using the 
principal components analysis of 5,545 ancestry informative markers. 
Genotypes were coded additively by the number of copies of the reference 
allele. Given the modest sample size and the large number of variables, the 
focus is on replicating genetic association cataloged in recent literature and 
knowledge-bases. These databases include the NHGRI Catalog of 
Published Genome-Wide Association Studies [39], Gene Ontology [40], 
and KEGG: Kyoto Encyclopedia of Genes and Genomes [41]. With 
additional data, we will attempt to extend well fitting statistical models will 
additional variables to explore associations that may be novel using 
likelihood ratio tests and penalized regression techniques. Genetic 
association analyses will be performed in [R] [42]. 
Preliminary descriptive analyses are reported in Tables 7 and 8 
below. Smoking has a huge impact on risk of colorectal cancer in this 
sample (p=0.000612). The risk of this cancer is increased five fold. There 
are several genetic variants implicated in colorectal cancer. 
 
5.3.9 Future Work 
We have formalizing our collaborations through the formation of a 
consortium of researchers studying nicotine addiction, smoking cessation, 
and attributable diseases in Indonesia. Updates on this consortium are 
available on the BDSRC website and includes information on the 
databases, tools, and resources developed throughout the study to support 
genomics research. In the future, researchers with data or ongoing studies 
will be invited to submit a request to join the consortium that will then be 
reviewed by an advisory committee that will be formed. We will also 
outreach to other research groups and clinics that currently exist in 
Indonesia to inform them of the project’s efforts. 
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Table 7.  Genotyping Study Participant Characteristics 
Description Overall Cases Controls P-value 
Age 54.1 (50.6) 54.1 (13.1) 50.6 (14.4) 0.097 
Gender:Female 73 (42.9%) 38 (42.7 %) 35 (43.2%) 0.946 
Ethnicity     
Bugis 83 (48.8%) 38 (22.4%) 45 (26.5%)  
Makassar 44 (25.9%) 24 (14.1%) 20 (11.8%)  
Mandar 3 (1.8 %) 2 (1.2%) 1 (0.6 %)  
Non South 
Sulawesi 13 (7.6 %) 9 (5.3%) 4 (2.4 %)  
Non Sulawesi 8 (4.7 %) 5 (2.9%) 3 (1.8%)  
Toraja 18 (10.6 %) 10 (5.9%) 8 (4.7%)  
BMI 21.1 (7.4) 19.8 (6.0) 22.8 (8.6) 0.020 
Smoking     
≥ 100 cigarettes 
in life       38 (27.0%) 31 (38.8%) 7 (11.5%) 0.000612 
 
A Statistical Analysis Plan (SAP) will be developed in order to 
formalize how data and results will be summarized across studies in the 
consortium and how evidence will be translated to precision medicine. The 
SAP will summarize the background, study design, study conduct and 
subject characteristics, and statistical methods. A standardized research 
consent form will be developed and made available to partner studies as 
part of the SAP. 
Additionally, we will pursue the linking of this project to 
international projects, such as those supported by National Institute on 
Drug Abuse (NIDA) of the United States, World Health Organization of 
the United Nations, the Psychiatric Genetics Consortium, and the Precision 
Medicine Initiative. Results from the study will be presented at an 
international conference, such as the annual conference held by the Society 
for Research on Nicotine and Tobacco. 
 
5.4     Scientific Relevance 
 
The first gap this study addresses is the understudied state of the 
Indonesian population. Indonesia has an ethnically and culturally diverse 
population that can offer great insights on treatment and disease processes. 
Conversely, heterogeneity makes it virtually impossible to have a standard 
protocol of treatment work maximally for every individual patient [22, 23]. 
The United Kingdom has a well-established national biobank that has 
facilitated studies ranging from cancer to eye disorders [43, 44]. 
Scandinavian countries are also in the process of recruiting and collecting  
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Table   8.  Marginal Association Scan Results 
Chr Pos Allele P-value OR 
7 19024682 T 2.15E-08 4.4 
9 5034454 A 1.22E-06 0.3 
19 19425025 C 1.39E-06 0.3 
15 25876991 C 1.64E-06 2.9 
3 11030852 T 1.77E-06 0.3 
5 76050452 G 1.78E-06 0.2 
5 176045442 C 2.05E-06 0.3 
9 9886403 C 2.25E-06 0.2 
7 2953442 A 2.26E-06 0.3 
9 5087495 C 2.39E-06 2.9 
1 116205021 A 2.74E-06 0.4 
7 19021083 A 3.00E-06 2.8 
4 515243 G 3.18E-06 0.3 
4 516586 A 3.84E-06 0.3 
11 133379079 C 4.25E-06 0.3 
14 33817553 G 5.23E-06 2.7 
17 8523722 A 5.25E-06 0.3 
15 94286895 A 5.48E-06 2.8 
7 14585513 C 6.04E-06 0.3 
16 81937574 T 6.19E-06 0.1 
4 175452245 C 6.61E-06 0.2 
1 194013039 G 6.83E-06 0.3 
4 21348980 C 7.67E-06 4.0 
23 83562000 A 8.47E-06 0.2 
3 61503354 A 8.65E-06 0.4 
2 24680249 G 8.73E-06 2.9 
3 72232520 A 9.03E-06 0.2 
9 5071049 G 9.42E-06 2.7 
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data for their national biobanks through universities, hospital networks, and 
commercial institutions [45, 48]. In Asia, South Korea have begun their 
biobank establishment [49] while China has multiple biobanking initiatives 
[50]. Malaysia, India, Singapore, and Thailand have their initiatives as well 
[51]. With some nations already performing research based on their 
national biobank and many others in the process of biospecimen curation, 
it is essential for Indonesia to build its own biobank. 
Through the work done in this study, our team will be able to begin 
identifying and replicating clinical and genetic factors important in an 
Indonesian population with tobacco related phenotypes. In order to do so, 
this study ad- dressed another scientific gap that often hampers big-data, 
biomedical research: the lack of uniform data. Support for standardized 
data collection of biospecimens and measures across studies [34], including 
demographics, substance use behaviors, history, and related risk factors, 
will permit meta-analyses of tests of association with tobacco use 
dependence and abstinence phenotypes. This biobank design will in turn 
serve as a template for future biobanking efforts in Indonesia for 
understanding and treating various complex diseases. 
Another gap this study addressed was a lack of collaborative research 
and data sharing among cancer researchers. The consortium established 
enables tobacco researchers to share methods and data, increasing sample 
sizes available to detect important factors. Support for an Indonesian 
biobank will provide the infrastructure and methods to encourage 
collaboration among multiple clinical researchers, each of whom will 
benefit from the availability and cost savings of standardized consents, 
measures, protocols, and biobanking. 
 
5.5    Broader Impacts 
 
This study impacts biomedicine and the Indonesian population by 
taking the step towards applying pharmacogenetics to assist treatment-
response optimization for smokers and cancer patients. The use of 
pharmacogenetics is virtually non-existent in Indonesia, including for 
smoking cessation [52]. Commencing a biobank is a daunting task; thus, a 
smaller-scale start with a clear and systematic approach based on a major 
public health issue (e.g. smoking, cancer) proved to be practical. Samples 
collected from this study achieved our goal to establish the first Indonesian 
Biobank, supported by refined strategies to manage and maintain it. 
Consistent data collection facilitates efforts in expansion, such as the 
inclusion of more ethnicities and regions, as well as the study of other 
addictions and smoking-related diseases. The most concrete potential 
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expansion is through Hasanuddin University’s study of colorectal cancer, 
a disease moderately but significantly associated with smoking [53]. With 
this study, we can share data and collaborate to design innovative studies. 
We have developed an extensive, international network to expand 
and utilize the Indonesian Biobank. 
 
5.6    Study Sustainability 
 
Uniform and detailed data on clinical and genetic factors related to 
tobacco use, treatment, and diseases based on a diverse population is 
extremely valuable to future research, facilitating the study of many facets 
of biomedicine based on the biodiversity and heterogeneity of the 
Indonesian population. Additionally, the resources developed in this grant 
can be used for future investigations of addiction beyond nicotine and 
colorectal cancer, and potential links to related diseases, such as lung 
cancer and cardiovascular diseases. The foundation of this study was 
gathering data using best practices based on our previous research and 
recommendations from our collaborators and literature. This represents the 
first biobank in Indonesia with data that can be used for multiple studies.  
We have formed and maintained a multitude of international and 
national collaborations with groups directly and indirectly interested in 
nicotine addiction and smoking cessation that will play critical roles in 
propelling the work that will be initiated by this project. In our studies of 
smokers in the United States, we have published original articles on 
methodology [27] and a pilot study [28]. Since 2014, we have consistently 
attended and presented our findings at the annual conference of Society for 
Research on Nicotine & Tobacco (SRNT), a global organization dedicated 
exclusively to nicotine and tobacco research with members from forty 
nations [57]. Additionally, the team is involved in multiple US National 
Institute on Drug Abuse (NIH/NIDA) contracts and grants 
(HHSN271201200005C, HHSN271201300004C, and 1R43DA041211-
01A1). The software, database, and statistical analysis tools are built in a 
manner that facilitates both research capacity and training for extensive, 
future collaborations. Furthermore, we hope to be able to both obtain 
further support from and stimulate local interest and involvement in order 
to establish a national biobank for Indonesia that covers multiple 
geographical regions and ethnicities. 
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5.7    Innovative Approaches 
 
It is estimated that an annual spending of 11 trillion Indonesian rupiah 
(an equivalent of 1.2 billion USD) originate from medical care related to 
tobacco- attributed diseases of the Indonesian population [1, 58]. An typical 
low-income household is found to spend financially 15 times more on 
tobacco products than on healthcare and 9 times more than on education 
[2]. It was also reported that for a significant portion of the low-income 
household, purchases of tobacco (12% of total monthly spending) often 
takes precedence over utility bills (water, electricity, phone bills), housing 
rent, and protein food sources; on average, many household ranks cigarette 
spending second to only the purchase of rice (22% of total monthly 
spending) [2]. 
Big-data medicine is the next big step in biomedical research efforts 
to solve issues stemming from complex diseases and disorders, such as 
nicotine addiction. Therefore, it is crucial that Indonesia begins to establish 
biobanks of clinical data and biospecimens that can serve as the foundation 
upon which future biomedical projects can be designed and studied. This 
study begins with colorectal cancer cases and controls, a subset of which 
are smokers. However, data collection, software design, and statistical 
methodologies were established with future precision medicine studies in 
mind. The study was also the first of its kind to layout the platform upon 
which medical genetics and pharmacogenetics can be utilized, eventually, 
to select effective treatments and prevention strategies for segments of the 
Indonesian population. 
The use of the Smokescreen Genotyping Array is innovative and 
aligns with similar ongoing genotyping initiatives by the US NIH/NIDA 
(Aim 3) [56]. The array is multi-purpose and customizable for studying a 
variety of diseases and disorders, which allows for a uniform technology 
that can support the progression of precision medicine work in Indonesia. 
Building the research capabilities in Indonesia with shared technology and 
international collaboration allows for data and results to be combined, 
providing more scientific value. 
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Chapter 6 
Commercialization Roadmap 
 
 
1. Continue to innovate and educate in high performance computing, 
genomics, and data science. 
 
 Through the surveys of physicians and smokers, we learned that there 
is great interest in medical genetics in Jakarta. However, there is a 
gap in knowledge on how to use genomic information and the avail- 
ability of treatments available for smokers wanting to quit. Thus 
education of physicians and smokers on new medications and 
screening technologies is needed for commercialization. 
 
 In the genotyping study we learned that extracting and shipping DNA 
samples internationally for genotyping is costly and inefficient. Thus 
the capacity to genotype or sequence DNA samples using high- 
throughput approaches in Indonesia is very much needed for all 
human genomic studies throughout the country. This represents a 
companion commercialization opportunity for BINUS, as there are 
not yet service providers in Indonesia. 
 
 Motivated by this research, BINUS has prepared for the data 
management and analysis requirements for genomic data, by 
investing in high performance computing and building partnerships 
with HPC partners such as NVIDIA and AWS. Continuing these 
activities and training are important for the analysis of genomic data. 
This represents another companion commercialization opportunity 
for BINUS, offering HPC and bioinformatics services for other 
studies. 
 
2. Continue to work with health care partners to collect data and DNA 
samples. The data from the Smokescreen genotyping project in 
Indonesia will be extremely useful for research. Discovering and 
validating biosignatures specific to an Indonesian population for clinical 
products will require big data. Therefore, an important part of a 
commercial path is to partner with organizations interested in this 
research to continue to build the research database. The database itself 
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could become an extremely valuable asset, it which pharmaceutical and 
health care networks may license access to high quality data. 
 
3. Use the data to build tools to help smokers quit and treat diseases in 
Indonesia. The culmination of data collection, high performance 
computing, and the education path described above is the ability for 
BINUS to use data science to build multiple health products for 
Indonesians. This includes tools to help doctors personalize medicine, 
for the smoker that wants to quit smoker, or the cancer patient to stand 
the optimal chance of survival. These products could be offered as a 
service provider where BINUS accepts samples and provides reports to 
the clinician, licensed to other organizations, or as direct to consumer 
where the patient plays a more active role in medical decision making 
based on information provided by us. 
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Chapter 7 
Key Accomplishments 
 
 
 Through the contributions of BINUS University and their 
collaborators, we have established the first biobank in Indonesia. 
While the initial biobank focuses on colorectal cancer and smoking 
behavior, the requirements for scaling are now known. 
 
 We have developed the IT infrastructure for data collection, 
management, and analysis of study data. This is composed of a secure 
relational database, web-based application, and statistical computing 
support form BINUS, NVIDIA and Amazon Web Services. This 
system is available for future studies. 
 
 The results of this research has been presented at international 
meetings and in scientific journals, including: 
 
– Pardamean B, Budiarto A, Caraka, RE. Indonesian Colorectal 
Cancer Consortium Data Science System, in preparation. 
– Pardamean CI, Baurley JW, Pardamean B. Pharmacotherapy 
and medical genetics for smoking cessation in Jakarta. 
International Journal of Business and Society, under review. 
– Pardamean CI, Baurley JW, Kacamarga MF, Pardamean B, 
Genetic screening for nicotine dependence and treatment 
approaches among physicians in Indonesia. International 
Journal of Pharmaceutical Sciences Review and Research, 
43(1), 2017. 
– Pardamean B, Baurley JW, Pardamean CI, Figueiredo JC. 
Changing colorectal cancer trends in Asians. Int J Colorectal 
Dis. 2016 Mar 29. 
– Baurley JW, et al. Smokescreen – a unified platform for 
addiction research. Society for Research on Nicotine and 
Tobacco Annual meeting. 2016.  
– Baurley JW. et al. Nicotine Metabolism in Multiple 
Populations. Society for Research on Nicotine and Tobacco 
Annual meeting. 2015. 
46 
 
– Baurley JW. et. al. Smokescreen: A Targeted Genotyping 
Array and Software Application for Nicotine Research. Society 
for Research on Nicotine and Tobacco Annual meeting. 2014. 
 
 NIDA Genetics Consortium members are aware of the study. There 
are opportunities for sharing of data and results as the biobank in 
Indonesia grows. 
 
 We have build strong international collaborations with industry 
(NVIDIA, Amazon Web Services, AVNET, and Affymetrix); 
Research institutions (USC, BioRealm, UNHAS, UCLA, Clemson, 
NTU); and sample processing labs (MRIN, RUCDR). 
 
 We have built BINUS’s high performance computing (HPC) capacity 
for data analysis of genomic data. This includes establishment of the 
NVIDIA GPU Education Center in 2015, its renewal in 2016, and 
expansion to an AI R&D Center to be launched summer 2017. In 
addition, ongoing education and research grants from Amazon Web 
Services have been awarded for cloud resources. 
 
 The first in Indonesia, an official material transfer agreement (MTA) 
for DNA transfer to the USA for genotyping was established. 
 
 Sparked collaborations with other research groups across the region 
(e.g., AsiaGenome, SGInnovate). 
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